Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...